132 related articles for article (PubMed ID: 35037086)
1. In Vivo Comparison of Micro-Balloon Interventions (MBI) Advantage: A Retrospective Cohort Study of DEB-TACE Versus b-TACE and of SIRT Versus b-SIRT.
Lucatelli P; De Rubeis G; Trobiani C; Ungania S; Rocco B; De Gyurgyokai SZ; Masi M; Pecorella I; Cappelli F; Lai Q; Catalano C; Vallati G
Cardiovasc Intervent Radiol; 2022 Mar; 45(3):306-314. PubMed ID: 35037086
[TBL] [Abstract][Full Text] [Related]
2. SIRT Compared with DEB-TACE for Hepatocellular Carcinoma: a Real-world Study (the SITAR Study).
Hirsch RD; Mills C; Sawhney R; Sood S; Bird V; Mishra G; Dev A; Kemp W; Lubel J; Roberts SK; Gow P; Nicoll AJ
J Gastrointest Cancer; 2021 Sep; 52(3):907-914. PubMed ID: 32901445
[TBL] [Abstract][Full Text] [Related]
3. Balloon occluded TACE (B-TACE) vs DEM-TACE for HCC: a single center retrospective case control study.
Lucatelli P; De Rubeis G; Rocco B; Basilico F; Cannavale A; Abbatecola A; Nardis PG; Corona M; Brozzetti S; Catalano C; Bezzi M
BMC Gastroenterol; 2021 Feb; 21(1):51. PubMed ID: 33535972
[TBL] [Abstract][Full Text] [Related]
4. Randomized comparison of selective internal radiotherapy (SIRT) versus drug-eluting bead transarterial chemoembolization (DEB-TACE) for the treatment of hepatocellular carcinoma.
Pitton MB; Kloeckner R; Ruckes C; Wirth GM; Eichhorn W; Wörns MA; Weinmann A; Schreckenberger M; Galle PR; Otto G; Dueber C
Cardiovasc Intervent Radiol; 2015 Apr; 38(2):352-60. PubMed ID: 25373796
[TBL] [Abstract][Full Text] [Related]
5. Balloon-Occluded Transcatheter Arterial Chemoembolization (b-TACE) for Hepatocellular Carcinoma Performed with Polyethylene-Glycol Epirubicin-Loaded Drug-Eluting Embolics: Safety and Preliminary Results.
Lucatelli P; Ginnani Corradini L; De Rubeis G; Rocco B; Basilico F; Cannavale A; Nardis PG; Corona M; Saba L; Catalano C; Bezzi M
Cardiovasc Intervent Radiol; 2019 Jun; 42(6):853-862. PubMed ID: 30843093
[TBL] [Abstract][Full Text] [Related]
6. Trans-arterial chemoembolization with degradable starch microspheres (DSM-TACE) versus selective internal radiation therapy (SIRT) in multifocal hepatocellular carcinoma.
Auer TA; Jonczyk M; Collettini F; Marth A; Wieners G; Hamm B; Gebauer B
Acta Radiol; 2021 Mar; 62(3):313-321. PubMed ID: 32498543
[TBL] [Abstract][Full Text] [Related]
7. Quantitative analysis with multiphase contrast-enhanced computed tomography to evaluate residual tumor activity of hepatocellular carcinoma after DEB-TACE.
Hu W; Cao G; Ye S; Xu J; Chen J; Shao G
Medicine (Baltimore); 2023 Jun; 102(24):e34054. PubMed ID: 37327303
[TBL] [Abstract][Full Text] [Related]
8. Retrospective analysis of the immunogenic effects of intra-arterial locoregional therapies in hepatocellular carcinoma: a rationale for combining selective internal radiation therapy (SIRT) and immunotherapy.
Craciun L; de Wind R; Demetter P; Lucidi V; Bohlok A; Michiels S; Bouazza F; Vouche M; Tancredi I; Verset G; Garaud S; Naveaux C; Galdon MG; Gallo KW; Hendlisz A; Derijckere ID; Flamen P; Larsimont D; Donckier V
BMC Cancer; 2020 Feb; 20(1):135. PubMed ID: 32075608
[TBL] [Abstract][Full Text] [Related]
9. Quantification of perfusion reduction by using 2D-perfusion angiography following transarterial chemoembolization with drug-eluting beads.
Maschke SK; Werncke T; Klöckner R; Rodt T; Renne J; Kirstein MM; Vogel A; Wacker FK; Meyer BC; Hinrichs JB
Abdom Radiol (NY); 2018 May; 43(5):1245-1253. PubMed ID: 28840307
[TBL] [Abstract][Full Text] [Related]
10. Conventional versus drug-eluting beads chemoembolization for infiltrative hepatocellular carcinoma: a comparison of efficacy and safety.
Zhang ZS; Li HZ; Ma C; Xiao YD
BMC Cancer; 2019 Nov; 19(1):1162. PubMed ID: 31783814
[TBL] [Abstract][Full Text] [Related]
11. Conventional Versus Small Doxorubicin-eluting Bead Transcatheter Arterial Chemoembolization for Treating Barcelona Clinic Liver Cancer Stage 0/A Hepatocellular Carcinoma.
Kang YJ; Lee BC; Kim JK; Yim NY; Kim HO; Cho SB; Jeong YY
Cardiovasc Intervent Radiol; 2020 Jan; 43(1):55-64. PubMed ID: 31646378
[TBL] [Abstract][Full Text] [Related]
12. Doxorubicin-eluting bead vs conventional transcatheter arterial chemoembolization for hepatocellular carcinoma before liver transplantation.
Nicolini D; Svegliati-Baroni G; Candelari R; Mincarelli C; Mandolesi A; Bearzi I; Mocchegiani F; Vecchi A; Montalti R; Benedetti A; Risaliti A; Vivarelli M
World J Gastroenterol; 2013 Sep; 19(34):5622-32. PubMed ID: 24039354
[TBL] [Abstract][Full Text] [Related]
13. Meta-analysis: adjusted indirect comparison of drug-eluting bead transarterial chemoembolization versus
Ludwig JM; Zhang D; Xing M; Kim HS
Eur Radiol; 2017 May; 27(5):2031-2041. PubMed ID: 27562480
[TBL] [Abstract][Full Text] [Related]
14. Intra arterial treatment of hepatocellular carcinoma: Comparison of MELD score variations between radio-embolization and chemo-embolization.
Delicque J; Hermida M; Piron L; Allimant C; Belgour A; Pageaux GP; Ben Bouallegue F; Assenat E; Mariano-Goulart D; Guiu B; Cassinotto C
Diagn Interv Imaging; 2019 Nov; 100(11):689-697. PubMed ID: 31281074
[TBL] [Abstract][Full Text] [Related]
15. Short-term efficacy and safety of callispheres drug-loaded microsphere embolization in primary hepatocellular carcinoma.
Li J; Wang N; Shi C; Liu Q; Song J; Ye X
J Cancer Res Ther; 2021 Jul; 17(3):733-739. PubMed ID: 34269307
[TBL] [Abstract][Full Text] [Related]
16. Prospective randomized comparison of chemoembolization with doxorubicin-eluting beads and bland embolization with BeadBlock for hepatocellular carcinoma.
Malagari K; Pomoni M; Kelekis A; Pomoni A; Dourakis S; Spyridopoulos T; Moschouris H; Emmanouil E; Rizos S; Kelekis D
Cardiovasc Intervent Radiol; 2010 Jun; 33(3):541-51. PubMed ID: 19937027
[TBL] [Abstract][Full Text] [Related]
17. CalliSpheres drug-eluting beads versus lipiodol transarterial chemoembolization in the treatment of hepatocellular carcinoma: a short-term efficacy and safety study.
Wu B; Zhou J; Ling G; Zhu D; Long Q
World J Surg Oncol; 2018 Mar; 16(1):69. PubMed ID: 29587773
[TBL] [Abstract][Full Text] [Related]
18. Five-year outcome of conventional and drug-eluting transcatheter arterial chemoembolization in patients with hepatocellular carcinoma.
Liu YS; Lin CY; Chuang MT; Lin CY; Tsai YS; Wang CK; Ou MC
BMC Gastroenterol; 2018 Aug; 18(1):124. PubMed ID: 30075752
[TBL] [Abstract][Full Text] [Related]
19. Correlation between SACE (Subjective Angiographic Chemoembolization Endpoint) score and tumor response and its impact on survival after DEB-TACE in patients with hepatocellular carcinoma.
Habbel VSA; Zeile M; Stavrou GA; Wacker F; Brüning R; Oldhafer KJ; Rodt T
Abdom Radiol (NY); 2019 Oct; 44(10):3463-3479. PubMed ID: 31332502
[TBL] [Abstract][Full Text] [Related]
20. Risk factors for local recurrence of hepatocellular carcinoma after transcatheter arterial chemoembolization with drug-eluting beads (DEB-TACE).
Nakano MM; Yamamoto A; Nishida N; Hamuro M; Hamamoto S; Jogo A; Sohgawa E; Kageyama K; Minami T; Miki Y
Jpn J Radiol; 2019 Jul; 37(7):543-548. PubMed ID: 31055710
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
